Teijin Gout (Febuxostat) – A Uric Acid-Lowering Treatment Option from Original Research in Japan
Share
After a beer, the joints ache like they're being stabbed with needles—this is a nightmare experienced by countless gout patients in the dead of night . Febuxostat, developed by Teijin Pharmaceutical in Japan, is providing a safer and more effective treatment option for patients with hyperuricemia worldwide as an original drug .
I. Teijin Research Institute of Japan: The Icebreaker in a 40-Year Dilemma
The field of gout treatment remained stagnant for nearly 40 years until Teijin Pharmaceutical of Japan launched febuxostat in 2009. As the world's first non-purine xanthine oxidase inhibitor , its development began in 1988—at a time when gout was not widely recognized and its market potential was not considered promising. However, Teijin Pharmaceutical persisted in its investment, verifying its safety and efficacy through more than 2,000 clinical trials, and finally launched it in Japan in 2011, quickly obtaining approval from the US FDA and the European EMA.
The core advantage of original drugs lies in:
● Precise targeting : Selectively inhibits the molybdenum pterin active site of xanthine oxidase (XO), blocking the "master switch" of uric acid synthesis.
● Dual-state inhibition : Simultaneously inhibits both oxidized and reduced XO, with an efficacy more than a thousand times that of allopurinol.
● Metabolic friendly : 49% is excreted via the kidneys and 45% via feces. No dose adjustment is required for patients with mild to moderate renal impairment , solving the problem of traditional drugs increasing the burden on the kidneys.
II. Clinical Status: First-line choice recommended by guidelines
1. A powerful tool for lowering uric acid levels and achieving target levels.
● Rapid acid control : After 2 weeks of treatment with a 40mg dose, 58% of patients saw their serum uric acid levels drop to <360μmol/L (compared to only 22% in the allopurinol group).
● Long-term benefits : Continuous use for one year can reduce the size of gouty tophi by 62% and decrease the risk of joint damage by 41%.
● Asian Advantage : The Asia-Pacific CONFIRMS trial confirmed that its uric acid-lowering target achievement rate was 3.1 times higher than that of allopurinol.
2. A better solution for special populations
● Patients with renal insufficiency : No dose reduction is needed when eGFR ≥ 30 mL/min. For patients with severe renal impairment (eGFR < 30), a starting dose of 20-40 mg/day is recommended.
● Individuals allergic to allopurinol : Avoid severe allergic reactions related to the HLA-B*5801 gene (such as Stevens-Johnson syndrome), which are more common in Asians.
● Individuals with concurrent heart or kidney disease : Japanese research has confirmed that it can slow the progression of kidney function in hypertensive patients (elevated eGFR is positively correlated with improved systolic blood pressure).
3. Consensus and recognition of international guidelines
|
guide |
Recommendations |
|
China Guide (2019) |
First-line uric acid-lowering drugs, starting at 20 mg/day, maximum 80 mg/day. |
|
US ACR (2020) |
It is the first choice for patients with allopurinol intolerance or HLA-B*5801 positivity. |
|
Japan Guide |
The only recommended drug for asymptomatic hyperuricemia, emphasizing a low-dose starting strategy. |
III. Scientific Medication Use: A Key Strategy for Risk Mitigation
1. Stepwise dose adjustment
● Start with 10mg/day → Increase to 20 mg/day after 2 weeks → Assess whether 40 mg/day is needed at week 7
● Target values : <360 μmol/L for those without tophi, <300 μmol/L for those with tophi/kidney damage.
2. Response to cardiovascular risk controversies
The 2018 CARES study suggested that febuxostat had a slightly higher risk of cardiovascular death (HR=1.34), but the 2020 Asian FAST study overturned this conclusion, confirming that its safety profile was comparable to that of allopurinol.
Current recommendation :
● Use with caution in patients with ischemic heart disease or heart failure.
● The risk is manageable for those with no history of myocardial infarction/stroke.
3. Prevention of metastatic onset
Initial treatment for 3-6 months should be combined with colchicine (0.5 mg/day) or NSAIDs to avoid a sudden drop in blood uric acid that could trigger acute arthritis.
IV. Original Drugs vs. Generic Drugs: Differences Go Beyond Ingredients
Although many companies produce generic versions of febuxostat, Teijin's original drug remains irreplaceable:
● Process advantages : Original drugs have higher bioavailability; domestic bioequivalence (BE) trials show that the Cmax of some generic drugs fluctuates by up to 15%.
● Precise Dosage : Offers a full range of strengths (10mg/20mg/40mg) and supports fine-tuned dosage adjustments.
● Safety Accumulation : 20 years of clinical data validates liver and kidney safety.
Case Study Implications : A comparative study conducted by a top-tier hospital showed that the rate of abnormal liver enzymes in patients using the original drug within 3 months was only 1.2%, significantly lower than that in the generic drug group (4.8% ) .
V. Future Outlook: Combined Treatment and Chronic Disease Management
1. New Trends in Drug Combination Therapy
a. SGLT2 inhibitors (such as empagliflozin): adjuvant uric acid lowering (reduction of 1.55 mg/dL), synergistically improving cardiac and renal outcomes.
b. URAT1 inhibitors : Dotinurad promotes excretion and is used in synergy with febuxostat for refractory gout.
2. The Three Pillars of Lifelong Management
a. Regularly monitor uric acid and cardiac and renal function.
b. Daily water intake should be ≥2000ml
c. Limit high-purine foods and abstain from alcohol.
Scientific choices lead to long-term stability and security.
Teijin gout medication (febuxostat), with its original drug quality and renal friendliness , has become a cornerstone drug for the treatment of hyperuricemia. However, medication is only one part of a systemic approach —only by combining individualized dosage adjustments, regular monitoring, and strict lifestyle interventions can long-term uric acid control be achieved .
🏆 Asakusa Cosmetics provides you with
✔️ Authentic Febuxostat
✔️ Hospital prescription
✔️ Online doctor consultation
✔️ Pharmacist's Medication Instructions
✔️ Comprehensive after-sales tracking service
⚠️ Friendly reminder: This article is for reference only. Please consult your doctor for specific medication advice.
---------------------------------------------------------------------------------------------------
📞Welcome to scroll down to contact customer service, purchase online, and have it shipped directly to your door.